<SEC-DOCUMENT>0001437749-22-007149.txt : 20220325
<SEC-HEADER>0001437749-22-007149.hdr.sgml : 20220325
<ACCEPTANCE-DATETIME>20220325070530
ACCESSION NUMBER:		0001437749-22-007149
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20220325
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220325
DATE AS OF CHANGE:		20220325

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Moleculin Biotech, Inc.
		CENTRAL INDEX KEY:			0001659617
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				474671999
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37758
		FILM NUMBER:		22768205

	BUSINESS ADDRESS:	
		STREET 1:		5300 MEMORIAL DRIVE
		STREET 2:		SUITE 950
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77007
		BUSINESS PHONE:		713-300-5160

	MAIL ADDRESS:	
		STREET 1:		5300 MEMORIAL DRIVE
		STREET 2:		SUITE 950
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77007
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>mbrx20220322_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:rr="http://xbrl.sec.gov/rr/2018-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:mbrx="http://www.mbrx.com/20220325"><head>
	<title>mbrx20220322_8k.htm</title>

	<!-- Generated by ThunderDome Portal - 3/24/2022 9:28:15 PM -->
<meta http-equiv="Content-Type" content="text/html" /></head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;"><div style="display: none">
<ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="d20228K" name="dei:AmendmentFlag">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d20228K" name="dei:EntityCentralIndexKey">0001659617</ix:nonNumeric>

</ix:hidden>
<ix:references>
<link:schemaRef xlink:href="mbrx-20220325.xsd" xlink:type="simple" />
</ix:references>
<ix:resources>
<xbrli:context id="d20228K">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2022-03-25</xbrli:startDate>
<xbrli:endDate>2022-03-25</xbrli:endDate>
</xbrli:period>
</xbrli:context>


</ix:resources>
</ix:header>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;"><b>UNITED STATES</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;"><b>WASHINGTON, D.C. 20549</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;"><b>FORM <ix:nonNumeric contextRef="d20228K" name="dei:DocumentType"><b>8-K</b></ix:nonNumeric></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;"><b>CURRENT REPORT</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;"><b>PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;"><b>DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): <ix:nonNumeric contextRef="d20228K" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate"><b>March 25, 2022</b></ix:nonNumeric></b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;">&#xa0;</div>

<div style="text-align: center;">
<div><img alt="mbrx20220322_8kimg001.jpg" src="mbrx20220322_8kimg001.jpg" /></div>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;"><ix:nonNumeric contextRef="d20228K" name="dei:EntityRegistrantName"><b>MOLECULIN BIOTECH, INC.</b></ix:nonNumeric></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;">(Exact Name of Registrant as Specified in its Charter)</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:middle;width:7%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20228K" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode"><span style="text-transform:uppercase;">Delaware</span></ix:nonNumeric></div>
			</td>
			<td style="vertical-align:middle;width:7.2%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20228K" name="dei:EntityFileNumber"><b>001-37758</b></ix:nonNumeric></div>
			</td>
			<td style="vertical-align:middle;width:7%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20228K" name="dei:EntityTaxIdentificationNumber"><b>47-4671997</b></ix:nonNumeric></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:7%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(State or Other Jurisdiction of Incorporation</div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">or Organization)</div>
			</td>
			<td style="vertical-align:top;width:7.2%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Commission File No.)</div>
			</td>
			<td style="vertical-align:top;width:7%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(I.R.S. Employer Identification No.)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;"><b><ix:nonNumeric contextRef="d20228K" name="dei:EntityAddressAddressLine1"><b>5300 Memorial Drive, Suite 950</b></ix:nonNumeric>, <ix:nonNumeric contextRef="d20228K" name="dei:EntityAddressCityOrTown"><b>Houston</b></ix:nonNumeric>, <ix:nonNumeric contextRef="d20228K" name="dei:EntityAddressStateOrProvince"><b>TX</b></ix:nonNumeric> <ix:nonNumeric contextRef="d20228K" name="dei:EntityAddressPostalZipCode"><b>77007</b></ix:nonNumeric></b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;">(Address of principal executive offices and zip code)</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;"><b>(<ix:nonNumeric contextRef="d20228K" name="dei:CityAreaCode"><b>713</b></ix:nonNumeric>) <ix:nonNumeric contextRef="d20228K" name="dei:LocalPhoneNumber"><b>300-5160</b></ix:nonNumeric></b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;">(Registrant&#8217;s telephone number, including area code)</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;">(Former name or former address, if changed from last report)</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<i>see </i>General Instruction A.2. below):</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:bottom;width:21.2%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><ix:nonNumeric contextRef="d20228K" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric>&#xa0; Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:21.2%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><ix:nonNumeric contextRef="d20228K" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric>&#xa0; Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:21.2%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><ix:nonNumeric contextRef="d20228K" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric>&#xa0; Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:21.2%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><ix:nonNumeric contextRef="d20228K" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric>&#xa0; Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c)).</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).&#xa0; Emerging growth company&#xa0;<ix:nonNumeric contextRef="d20228K" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#xa0;&#9744;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:7.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Title of each class</b></div>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:6.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Trading Symbol (s)</b></div>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:7.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Name of each exchange on which registered</b></div>
			</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:7.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20228K" name="dei:Security12bTitle">Common Stock</ix:nonNumeric>, par value $.001 per share</div>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:6.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20228K" name="dei:TradingSymbol">MBRX</ix:nonNumeric></div>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:7.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">The <ix:nonNumeric contextRef="d20228K" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric> Stock Market LLC</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&#xa0;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="text-align: left; width: 100%">&#xa0;</div>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><b>Item 2.02</b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b>Results of Operations and Financial Condition.</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:36pt;">On March 25, 2022, Moleculin Biotech, Inc. (the &#8220;Company&#8221;) issued a press release announcing its financial results for the year ended December 31, 2021 and recent operational highlights. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><b>Item 9.01 </b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b>Financial Statements and Exhibits.</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">(d)&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;Exhibits.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align: top; width: 7%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Exhibit No. </b></div>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Description</b></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align: top; width: 7%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">99.1</div>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="ex_349962.htm" style="-sec-extract:exhibit;">Press Release dated March 25, 2022</a></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align: top; width: 7%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">104</div>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Cover page Interactive Data File (embedded within the Inline XBRL document)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;"><b><span style="text-decoration: underline;">SIGNATURE</span></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:36pt;">Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:middle;width:10.6%;">&#xa0;</td>
			<td style="vertical-align:middle;width:10.6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>MOLECULIN BIOTECH, INC.</b></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:10.6%;">&#xa0;</td>
			<td style="vertical-align:middle;width:10.6%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:10.6%;">&#xa0;</td>
			<td style="vertical-align:middle;width:10.6%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:10.6%;">&#xa0;</td>
			<td style="vertical-align:middle;width:10.6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Date: March 25, 2022</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:10.6%;">&#xa0;</td>
			<td style="vertical-align:middle;width:10.6%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:10.6%;">&#xa0;</td>
			<td style="vertical-align:middle;width:10.6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By: <span style="text-decoration: underline;">/s/ Jonathan P. Foster</span></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:10.6%;">&#xa0;</td>
			<td style="vertical-align:middle;width:10.6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Jonathan P. Foster</div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Chief Financial Officer</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center;">2</div>
</div>
</div>
</div>


</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex_349962.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html><head>
	<title>ex_349962.htm</title>
	<!-- Generated by ThunderDome Portal - 3/24/2022 8:16:56 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="margin-bottom: 0px; text-align: right; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 99.1</b></font></p>

<p style="margin-bottom: 0px; text-align: right; margin-top: 0px">&nbsp;</p>

<div><img alt="mbrx20220322_8kimg001.jpg" src="mbrx20220322_8kimg001.jpg"></div>

<div>&nbsp;</div>

<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;"><b>Moleculin Reports Full Year Financial Results and Provides Programs Update</b></p>

<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;"><i>&#8211; Preliminary positive safety and efficacy data from second Phase 1 AML study supports plans to explore a Phase 1/2 of Annamycin in combination with Cytarabine </i>&#8211;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;"><i>&#8211; Preliminary interim data for Annamycin in three Phase 1 clinical trials for Acute Myeloid Leukemia (AML) and metastases of Soft Tissue Sarcoma (STS) continues to demonstrate the absence of cardiotoxicity, representing a significant advancement in patient safety </i>&#8211;<i> </i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;"><i>&#8211; WP1122 advancing with parallel development toward first-in-human Phase 1a study to evaluate safety and pharmacokinetics in healthy volunteers for the treatment of COVID-19 and potential treatment of glioblastoma multiforme (GBM) </i>&#8211;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;"><i>&#8211; Multiple key clinical and regulatory milestones expected throughout 2022 </i>&#8211;<i> </i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>&#8211; Company has sufficient capital to fund operations into 2024 </i>&#8211;<i> </i></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>HOUSTON, March 25, 2022 /PRNewswire/ -- Moleculin Biotech, Inc.</b>, (Nasdaq: MBRX) (&#8220;Moleculin&#8221; or the &#8220;Company&#8221;), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today reported its financial results for the year ended December 31, 2021. The Company also provided an update on its portfolio of oncology drug candidates for the treatment of highly resistant tumors and viruses.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#8220;Over the course of 2021, we have made significant progress across multiple fronts. As we look ahead, I believe we are well positioned for an exciting 2022 with a number of clinical and regulatory milestones expected throughout the year,&#8221; commented Walter Klemp, Chairman and CEO of Moleculin. &#8220;Our Annamycin development programs in STS lung mets and AML continue to progress and we remain encouraged by the data seen to date. Additionally, with the necessary regulatory approvals received, we are advancing parallel development of WP1122 for the treatment of COVID-19 and GBM. With our growing body of encouraging clinical data and our strong financing position, we remain laser focused on executing our initiatives, driving value for all stakeholders, and importantly, addressing unmet needs for people with highly resistant tumors and viruses.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><b>Recent Highlights </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:26pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Appointed Joy Yan, M.D., Ph.D., an oncology physician-scientist with extensive experience in early and late clinical development with successful track record, to its Board of Directors.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:26pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Successfully concluded the Company&#8217;s second Phase 1 trial (MB-105) in Poland evaluating Annamycin for the treatment of relapsed and refractory acute myeloid leukemia (AML), where Moleculin determined a dose of 240 mg/m<sup style="vertical-align:top;line-height:120%;font-size:pt">2</sup> as the Recommended Phase 2 Dose (RP2D) and demonstrated no signs of cardiotoxicity (a common problem with currently prescribed anthracyclines).</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:26pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Reported an updated independent safety review of certain preliminary data for the first 30 patients in its three Phase 1 clinical trials with Annamycin targeting relapsed or refractory AML and the metastases of soft tissue sarcoma to the lungs (STS Lung), which concluded there was no evidence of cardiotoxicity. The review included analysis of ejection fraction, echo strain and certain troponin levels intended to assess potential for both acute and chronic heart damage. Additionally, the Company reported evidence that Annamycin may have a substantially lower incidence of alopecia (hair loss) than currently prescribed anthracyclines such as doxorubicin.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:26pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Reported preliminary interim results from its U.S. Phase 1b/2 clinical trial evaluating Annamycin for the treatment of STS lung metastases in its fourth cohort with three patients recruited and dosed which continues to document preliminary human activity for this drug. In this cohort one patient experienced a dose limiting toxicity (DLT) that resolved and continues in the trial. All three initial patients had their scans after two cycles and reported stable disease and are continuing in the study. This information is preliminary and subject to change.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:26pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Received allowance from the U.S. Food and Drug Administration (FDA) for the Company's Investigational New Drug (IND) application to study WP1122 for the treatment of GBM. With this IND now cleared, Moleculin plans to identify investigators interested in initiating a Phase 1 open label, single arm, dose escalation study of the safety, pharmacokinetics and efficacy of oral WP1122 in adult patients with GBM.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:26pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Filed an amended protocol with both the Riverside Ethics Committee and Medicines and Healthcare Products Regulatory Agency (MHRA) to commence a Phase 1a clinical trial of WP1122 in the United Kingdom; once approved, the internally funded trial is expected to begin in the first half of 2022.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Programs Update </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Next Generation Anthracycline - Annamycin</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Annamycin is the Company's next-generation anthracycline that has been shown in animal models to accumulate in the lungs at up to 30-fold the level of doxorubicin, as well as demonstrating the ability to avoid the multidrug resistance mechanisms that typically limit the efficacy of doxorubicin and other currently prescribed anthracyclines. Importantly, Annamycin has also demonstrated a lack of cardiotoxicity in multiple human clinical trials, including ongoing trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases, and the Company believes that the use of Annamycin may not face the same usage limitations imposed on doxorubicin, one of the most common currently prescribed anthracyclines. Annamycin is currently in development for the treatment of AML and STS lung metastases and the Company believes it may have the potential to treat a number of additional indications.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Annamycin currently has Fast Track Status and Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of STS lung metastases, in addition to Orphan Drug Designation for the treatment of relapsed or refractory acute myeloid leukemia.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">For more information about the Phase 1b/2 study evaluating Annamycin for the treatment of STS lung metastases, please visit clinicaltrials.gov and reference identifier NCT04887298.&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Upcoming Milestones Expectations</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">H1 2022: Initiate Phase 1/2 study in Europe for the treatment of AML evaluating combination therapy of Annamycin + Ara-C.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">H1 2022: Commencement of an investigator-funded, second Phase 1b/2 clinical trial of Annamycin in sarcoma lung metastases in Europe.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">H1 2022: Complete Phase 1b portion of ongoing Phase 1b/2 study of Annamycin for the treatment of sarcoma lung metastases in the US.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Metabolism/Glycosylation Inhibitor </b>&#8211;<b> WP1122</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Moleculin has new compounds designed to target the roles of glycolysis and glycosylation in both cancer and viral diseases. The Company&#8217;s lead Metabolism/Glycosylation Inhibitor, WP1122, is a prodrug of 2-DG that appears to improve the drug-like properties of 2-DG by increasing its circulation time and improving tissue/organ distribution.&nbsp;Based on recently published research that has identified that 2-DG has antiviral potential against SARS-CoV-2 <i>in vitro</i>, Moleculin believes WP1122 has significant potential as a COVID-19 therapy.&nbsp;Its unique mechanism of action may also be well-suited for combinations that potentiate existing therapies, including checkpoint inhibitors.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>COVID-19 </i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company has received authorization from the Medicines and Healthcare Products Regulatory Agency (MHRA) to commence a Phase 1a clinical trial of WP1122 in the United Kingdom. The Company also received a favorable opinion from the London &#8211; Riverside Research Ethics Committee in the UK to begin the study, which is expected to be conducted at the Medicines Evaluation Unit in Manchester, United Kingdom. In early March 2022, the Company filed an amended protocol with both the Riverside Ethics Committee and the MHRA. The amendment updated the dilution of the oral solution to achieve full dissolution of WP1122. No risk/benefit to the study was affected because of this change. The Phase 1a study in healthy human volunteers will investigate the effects of a single ascending dose (SAD) and multiple days of ascending dosing (MAD) of WP1122 administered as an oral solution. Dose escalation will take place in sequential SAD cohorts, and MAD will start as soon as SAD has completed at least 3 dosing cohorts in which WP1122 is found to be safe and well-tolerated. This study in healthy volunteers will explore safety and pharmacokinetics (PK), and subsequent clinical development will be in patients infected with SARS-CoV-2 to further evaluate safety and establish a favorable risk/benefit profile. The Company expects to enroll approximately 80 healthy volunteers in the United Kingdom.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Glioblastoma Multiforme</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Additionally, the Company recently announced that the FDA is allowing the Company's Investigational New Drug (IND) application to study WP1122 for the treatment of GBM to go forward. With this IND now cleared, Moleculin plans to identify investigators who are interested in initiating a Phase 1 open label, single arm, dose escalation study of the safety, pharmacokinetics and efficacy of oral WP1122 in adult patients with GBM.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Upcoming Milestones Expectations</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">H1 2022: Commence Phase 1a study of WP1122 for the treatment of COVID-19 in the UK.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">H1 2022: Potential to launch Phase 2 pivotal study of WP1122 for the treatment of COVID-19 outside of the US.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2022: Identify investigators interested in initiating a Phase 1 open label, single arm, dose escalation study of the safety, pharmacokinetics and efficacy of oral WP1122 in adult patients with GBM.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Ongoing preclinical development work in additional anti-viral indications such as HIV, Zika, and Dengue. Collaborations targeted for 2022.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Summary of Financial Results for the Full Year 2021</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Research and development (R&amp;D) expense was $14.4 million and $12.8 million for the year ended December 31, 2021 and 2020, respectively. The increase in R&amp;D of $1.6 million is mainly related to increase in the number of internally funded clinical trials and overall clinical trial activity, and costs related to manufacturing of additional drug product.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">General and administrative expense was $8.4 million and&nbsp;$6.8&nbsp;million for the year ended December 31, 2021 and 2020, respectively. The increase of&nbsp;$1.6&nbsp;million is mainly related to an increase&nbsp;in headcount, consulting and advisory fees, and an increase in our corporate insurance.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">For the year ended December 31, 2021 and 2020, the Company incurred net losses of $15.9 million which included non-cash gains of $6.7 million on warrants in 2021 as compared to $2.3 million in the prior year and approximately $2.4 million of stock-based compensation expense in 2021 as compared to $1.7 million in 2020.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company ended the year with $70.9 million of cash. The Company believes that this cash is sufficient to meet its projected operating requirements, which include a forecasted increase over its current R&amp;D rate of expenditures, into 2024.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>About Moleculin Biotech, Inc.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of highly resistant tumors and viruses. The Company&#8217;s lead program, Annamycin is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of COVID-19 and other viruses, as well as cancer indications including brain tumors, pancreatic and other cancers.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">For more information about the Company, please visit www.moleculin.com and connect on Twitter, LinkedIn and Facebook.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Forward-Looking Statements</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><br>
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the Company's ability to meet the milestones described in this release under the sections &#8220;Upcoming Milestones Expectations&#8221; and the Company's forecasted cash burn rate. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Moleculin has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. "Risk Factors" in our most recently filed Form 10-K filed with the Securities and Exchange Commission ("SEC") and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Investor Contact:</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">JTC Team, LLC</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Jenene Thomas</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(833) 475-8247</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>MBRX@jtcir.com</u></p>

<p>&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>-- Financial Tables Follow--</b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 62%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Moleculin Biotech, Inc.</b></p>
			</td>
			<td id=".lead.B2" style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".symb.B2" style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);"><b>&nbsp;</b></td>
			<td id=".amt.B2" style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);"><b>&nbsp;</b></td>
			<td id=".trail.B2" style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);"><b>&nbsp;</b></td>
			<td id=".lead.B3" style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".symb.B3" style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);"><b>&nbsp;</b></td>
			<td id=".amt.B3" style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);"><b>&nbsp;</b></td>
			<td id=".trail.B3" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"><b>&nbsp;</b></td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Unaudited Condensed Consolidated Balance Sheets </b></p>
			</td>
			<td id=".lead.B2" style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".symb.B2" style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&nbsp;</b></td>
			<td id=".amt.B2" style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&nbsp;</b></td>
			<td id=".trail.B2" style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&nbsp;</b></td>
			<td id=".lead.B3" style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".symb.B3" style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&nbsp;</b></td>
			<td id=".amt.B3" style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&nbsp;</b></td>
			<td id=".trail.B3" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"><b>&nbsp;</b></td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>(in thousands)</b></p>
			</td>
			<td id=".lead.D2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, 2021</b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, 2020</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Current assets:</p>
			</td>
			<td id=".lead.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">70,903</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">15,173</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Prepaid expenses and other current assets</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">1,594</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">2,025</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total current assets</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">72,497</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">17,198</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Furniture and equipment, net</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">338</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">483</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Intangible assets</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,148</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,148</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating lease right-of-use asset</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">107</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">202</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total assets</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">84,090</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">29,031</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Current liabilities:</p>
			</td>
			<td id=".lead.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accounts payable and accrued expenses and other current liabilities</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">3,622</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">2,920</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total current liabilities</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,622</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,920</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating lease liability - long-term, net of current portion</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">63</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">159</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Warrant liability - long term</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,412</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,192</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total liabilities</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,097</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,271</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total stockholders' equity</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">78,993</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">17,760</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total liabilities and stockholders' equity</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">84,090</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">29,031</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Unaudited Condensed Consolidated Statements of Operations</b></p>
			</td>
			<td id=".lead.B2" style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".symb.B2" style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&nbsp;</b></td>
			<td id=".amt.B2" style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&nbsp;</b></td>
			<td id=".trail.B2" style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&nbsp;</b></td>
			<td id=".lead.B3" style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".symb.B3" style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&nbsp;</b></td>
			<td id=".amt.B3" style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&nbsp;</b></td>
			<td id=".trail.B3" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"><b>&nbsp;</b></td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="6" id=".amt.D3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year Ended December 31,</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>(in thousands, except share and per share amounts)</b></p>
			</td>
			<td id=".lead.D2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Revenues</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating expenses:</p>
			</td>
			<td id=".lead.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Research and development</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">14,418</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,757</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">General and administrative and depreciation</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,550</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,985</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total operating expenses</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">22,968</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">19,742</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Loss from operations</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(22,968</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(19,742</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other income:</p>
			</td>
			<td id=".lead.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Gain from change in fair value of warrant liability</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,728</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,346</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other income, net</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">40</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">28</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Interest income, net</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">306</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">13</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net loss</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(15,894</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(17,355</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net loss per common share - basic and diluted</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(0.59</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(1.76</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted average common shares outstanding - basic and diluted</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">26,875,927</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">9,845,685</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>mbrx-20220325.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 3/24/2022 9:28:17 PM-->
<xsd:schema xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:mbrx="http://www.mbrx.com/20220325" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.mbrx.com/20220325">
<xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/stpr/2021" schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"/>
<xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
<xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/sic/2021" schemaLocation="https://xbrl.sec.gov/sic/2021/sic-2021.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/currency/2021" schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/exch/2021" schemaLocation="https://xbrl.sec.gov/exch/2021/exch-2021.xsd"/>

<xsd:annotation>
<xsd:appinfo>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mbrx-20220325_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mbrx-20220325_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mbrx-20220325_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
<link:roleType id="statement-document-and-entity-information" roleURI="http://www.mbrx.com/20220325/role/statement-document-and-entity-information">
<link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:presentationLink</link:usedOn>
</link:roleType>
</xsd:appinfo>
</xsd:annotation>
<xsd:element abstract="true" id="mbrx_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>mbrx-20220325_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 3/24/2022 9:28:17 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
<link:roleRef roleURI="http://www.mbrx.com/20220325/role/statement-document-and-entity-information" xlink:href="mbrx-20220325.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:definitionLink xlink:role="http://www.mbrx.com/20220325/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>

<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>


<link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>mbrx-20220325_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 3/24/2022 9:28:17 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
<link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Type</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Period End Date</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Registrant Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Incorporation, State or Country Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, File Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityTaxIdentificationNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Tax Identification Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Address Line One</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, City or Town</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, State or Province</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Postal Zip Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:label xlink:label="dei_WrittenCommunications-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:label xlink:label="dei_SolicitingMaterial-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementIssuerTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Emerging Growth Company</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:label xlink:label="dei_Security12bTitle-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:label xlink:label="dei_SecurityExchangeName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Central Index Key</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>

</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>mbrx-20220325_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 3/24/2022 9:28:17 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.mbrx.com/20220325/role/statement-document-and-entity-information" xlink:href="mbrx-20220325.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:presentationLink xlink:role="http://www.mbrx.com/20220325/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>

<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>

<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>mbrx20220322_8kimg001.jpg
<TEXT>
begin 644 mbrx20220322_8kimg001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  \ .,# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBL3Q%>
M:M';BTT*T\V^F'$TA C@7^\Q/4^@&:J,>9V%*7*KCM<\4Z1X>0?VA=!96&5A
M0;I&^BCM[GBN%O/C#\Y%CI&5_O7$V"?P4'^=2VWPHFNY7N=;UF22>4[I/(7)
M)]W;.?R%;<7PO\-1J \5U+[O<L/Y8KO@L'37O7D_Z]#@F\94?N6BCF(?C#=!
MQY^D0,N>?+G8']5KK-#^(NA:S(D#R/97#'"QW& &/H&'!^G6F/\ #'PPXPMM
M<)[K<O\ U)K'O_A#9.K&PU*>)CT6=%D7Z<8-.3P-31)Q_KYDQ6.@[MJ1Z317
M"^&_^$C\,3IIFM1F\TQCMAO8F,GDGL&S\P4^ISM]<=.ZKAJT^25D[KN=U.?.
MKM684445F:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5E7_ (CT72VVWNJ6D+_W&E&[\NM7KRU2]LI[65G6.9#&Q1MK $8.#V-<
MS%\-?"L0P-.9O4M<2<_^/5K35+_EXW\C*HZG_+M+YBO\2/"R,5&HNV.ZV\A'
M_H-6+;Q]X7N3A=7@0GM,&C_]" JG-\,O#$JD):SPY[QW+_U)%<YJ?PB94+:5
MJ9) XCNEQG_@2_X&NJ,,'+3F:]3FE/&1UY4_2YZ=!<P740EMYHY8ST:-@P/X
MBI:^=+FPU_P?? NMS82D_+)$V%D^C#AOH?RKM/#7Q6D5DMM?3>G3[7$OS#_>
M4=?JOY553+IJ/-2?,B*>8P<N2JN5GJ]%16]Q#=V\=Q;RI+#(NY)$;(8>H-2U
MYVQZ)P/B#XEIH.NW6F'2FF,!4>8)PN<J&Z8]ZU?"'C.+Q6;M!:&UDM]IVF3?
MN4YYZ#N#7FWBM5?XK2*P!4WEL"#W&(\U=\*D^&OBC/IK?+%++); 9XP?GC/Y
M8'XUZ\\+2]A>*][EO_F>3#%5?;>\_=YFO\CUK4[^+2]+NK^;_5V\32,/7 SB
MO.3\8D .=$?('(^TC_XFM7XJZH+3PW%8JV'O9@&Y_@3YC^NT?C7F_B+2SI>C
M:"CIMFGLY+B3C!R[9 /T&!48/#4IP3J*]WI\B\9B*L)-4W:RU^9[[9W'VJR@
MN=NWS8U?;G.,C.*GKGIM?L/#OA2QO+^0A3;QJD:#+R-M' '^0*Y)OBU*2TT7
MA^5K1&PTAF/'U(4J#^-<<,+5J7<%H=D\33IZ3>IZ=VKB/#OQ"7Q!KZZ6-,:#
M*N?,,P;[OMBMGPWXKT_Q/;2/:%XYHO\ 6P28W+Z'C@CW%>6_#C_D?X_]R>MJ
M.'7)4]HM8HQJUWST^1Z29[A17$^(OB/8Z-?MI]I:R7]XC;'"-M56_NYP23[
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M\I-='M5&='M:S_ P5*4H5M-;W7WG#^)[E?&7C[3=.MVWVVV./@]F'F2'_OG
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M1117,=(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
'%%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140621899665320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Mar. 25, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity, Registrant Name</a></td>
<td class="text">MOLECULIN BIOTECH, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document, Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document, Period End Date</a></td>
<td class="text">Mar. 25,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity, Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity, File Number</a></td>
<td class="text">001-37758<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity, Tax Identification Number</a></td>
<td class="text">47-4671997<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity, Address, Address Line One</a></td>
<td class="text">5300 Memorial Drive, Suite 950<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity, Address, City or Town</a></td>
<td class="text">Houston<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity, Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity, Address, Postal Zip Code</a></td>
<td class="text">77007<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">300-5160<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity, Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MBRX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity, Central Index Key</a></td>
<td class="text">0001659617<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>mbrx20220322_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mbrx-20220325.xsd" xlink:type="simple"/>
    <context id="d20228K">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
        </entity>
        <period>
            <startDate>2022-03-25</startDate>
            <endDate>2022-03-25</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="d20228K">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="d20228K">0001659617</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="d20228K">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="d20228K">2022-03-25</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="d20228K">MOLECULIN BIOTECH, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="d20228K">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="d20228K">001-37758</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="d20228K">47-4671997</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="d20228K">5300 Memorial Drive, Suite 950</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="d20228K">Houston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d20228K">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d20228K">77007</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="d20228K">713</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d20228K">300-5160</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="d20228K">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="d20228K">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="d20228K">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="d20228K">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="d20228K">false</dei:EntityEmergingGrowthCompany>
    <dei:Security12bTitle contextRef="d20228K">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d20228K">MBRX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="d20228K">NASDAQ</dei:SecurityExchangeName>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " "N.'E4.JJBYT !   \ @
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MZ7FFUS>36TGHX-R#8._AE8P=S8\?=_<#4$L#!!0    ( *XX>50D'INBK0
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M;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ KCAY5"*VSH+N    *P(  !$
M             ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @
MKCAY5)E<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H
M96UE,2YX;6Q02P$"% ,4    " "N.'E4[R75UC<$  !8$   &
M    @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @
MKCAY5)^@&_"Q @  X@P   T              ( !>@P  'AL+W-T>6QE<RYX
M;6Q02P$"% ,4    " "N.'E4EXJ[',     3 @  "P              @ %6
M#P  7W)E;',O+G)E;'-02P$"% ,4    " "N.'E4.JJBYT !   \ @  #P
M            @ $_$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ KCAY
M5"0>FZ*M    ^ $  !H              ( !K!$  'AL+U]R96QS+W=O<FMB
M;V]K+GAM;"YR96QS4$L! A0#%     @ KCAY5&60>9(9 0  SP,  !,
M         ( !D1(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^
) @  VQ,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="mbrx20220322_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mbrx.com/20220325/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="mbrx20220322_8k.htm">mbrx20220322_8k.htm</File>
    <File>ex_349962.htm</File>
    <File>mbrx-20220325.xsd</File>
    <File>mbrx-20220325_def.xml</File>
    <File>mbrx-20220325_lab.xml</File>
    <File>mbrx-20220325_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>mbrx20220322_8kimg001.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "mbrx20220322_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "local": [
      "mbrx-20220325_def.xml"
     ]
    },
    "inline": {
     "local": [
      "mbrx20220322_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mbrx-20220325_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mbrx-20220325_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "mbrx-20220325.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd",
      "https://xbrl.sec.gov/exch/2021/exch-2021.xsd",
      "https://xbrl.sec.gov/sic/2021/sic-2021.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"
     ]
    }
   },
   "elementCount": 26,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "mbrx",
   "nsuri": "http://www.mbrx.com/20220325",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "mbrx20220322_8k.htm",
      "contextRef": "d20228K",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000 - Document - Document And Entity Information",
     "role": "http://www.mbrx.com/20220325/role/statement-document-and-entity-information",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "mbrx20220322_8k.htm",
      "contextRef": "d20228K",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20220325/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20220325/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20220325/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document, Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20220325/role/statement-document-and-entity-information"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document, Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20220325/role/statement-document-and-entity-information"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity, Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20220325/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity, Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20220325/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity, Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20220325/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity, Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20220325/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity, Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20220325/role/statement-document-and-entity-information"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20220325/role/statement-document-and-entity-information"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity, Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20220325/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity, File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20220325/role/statement-document-and-entity-information"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity, Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20220325/role/statement-document-and-entity-information"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity, Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20220325/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity, Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20220325/role/statement-document-and-entity-information"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20220325/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20220325/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20220325/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20220325/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20220325/role/statement-document-and-entity-information"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20220325/role/statement-document-and-entity-information"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20220325/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20220325/role/statement-document-and-entity-information"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20220325/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001437749-22-007149-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-22-007149-xbrl.zip
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M^= GT*  I0"L@:RKI-M32<P(FBV^?)0)=Z2\@/M]!HP-"PVN2J0M;!Y(1*W
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M@Y&C$.AAQHHXQ %UFZL TGTXVDKN%EON3J6K03\WCHT@!' +]JUF 4*8Y/L
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MX49&(&^ISM2*L=Y5-VD@$2PK"I%KTTN"R'T[NFJL;V]OM7:VZR^>GUD%VJI
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M&G] "=R9EGDQ,R/0T=>H3^2O\S$0C^3+?36\RZ4?Q>SR\.*R=J3^66NQ?7D
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M:4C":@8TP5^[%<RC6Y"F818NB3+I;<"EI:W,L,;)JO["YP]02P,$%     @
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MN2M;#*Z.Z2A)5L#/XJOM4GJ>N8V!1W)AOW"V%@O):8GH1IMHC.@R=RD$*WE
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MX".+# 5)'H,]9=X$*\2Q]&?@LE"!Y)BIJ._&,IZ&!?Z)?EZ,ES?(HCGE]D?
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MVUJYTFC!7V*NT)^-J_\?4$L#!!0    ( *XX>51; T^#_PT  ,L.   9
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MX)\6XG+V/P!02P$"% ,4    " "N.'E4\/JCLMX@  !_. $ #0
M    @ $     97A?,S0Y.38R+FAT;5!+ 0(4 Q0    ( *XX>53'MQUG>P,
M "\.   1              "  0DA  !M8G)X+3(P,C(P,S(U+GAS9%!+ 0(4
M Q0    ( *XX>52,IN7FW00  %$M   5              "  ;,D  !M8G)X
M+3(P,C(P,S(U7V1E9BYX;6Q02P$"% ,4    " "N.'E4_%?<'/H%  "K/
M%0              @ '#*0  ;6)R>"TR,#(R,#,R-5]L86(N>&UL4$L! A0#
M%     @ KCAY5*4P('EY!   Y2T  !4              ( !\"\  &UB<G@M
M,C R,C S,C5?<')E+GAM;%!+ 0(4 Q0    ( *XX>51]:IYN#@X  -94   3
M              "  9PT  !M8G)X,C R,C S,C)?.&LN:'1M4$L! A0#%
M  @ KCAY5%L#3X/_#0  RPX  !D              ( !VT(  &UB<G@R,#(R
G,#,R,E\X:VEM9S P,2YJ<&=02P4&      < !P#+ 0  $5$

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
